Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

September 22, 2023

Myth Busting: Master Protocol Edition

Interest and appetite for master protocols is growing as sponsors consider opportunities in various therapeutic areas...

Read article

June 14, 2023

Embracing Innovation: Exploring the Design of Umbrella and Basket Trials

Medical research has come a long way in recent years, fueled by innovative trial designs that challenge traditional...

Read article

May 7, 2020

Weekly Insights from the COVID-19 Trial Tracker: Oxford Vacine Study

There are now over 950 trials registered, which means that 250 new trials were registered in the past week. Only 540 of...

Read article

May 7, 2020

COVID-19: Trials, Designs and Tools for Promising Results - A Virtual Panel Discussion

An extraordinary amount of global research is underway as the COVID-19 pandemic continues to evolve and spread...

Read article

March 31, 2020

Key Design Thoughts for Basket Trials and Umbrella Trials by Jay Park

Since 1953, when the discovery of the structure of DNA was made, we have seen great advancements in genomics....

Read article

March 12, 2020

Interview with Jay Park: The present and future of Master Protocols

In September 2018, the FDA provided a draft guidance on master protocols reflecting an increased interest in these...

Read article